Multi-omics Mass Spectrometry & Biomarker Discovery Core Facility Shared Resource ABSTRACT The Multi-omics Mass Spectrometry & Biomarker Discovery Core Facility (MMSBD) provides Cancer Center (CC) members with mass spectrometry (MS)-based multi-omics technology to support research on cancer pathogenesis, cancer biomarkers, novel anti-cancer agents, and diagnostic studies. The multi-omics approaches provided encompass high-quality MS services for proteomics, peptidomics, glycomics, lipidomics, metabolomics, and small molecule analyses. Quantitative phosphoproteomics and deep proteomics are new services provided during the current funding period. The Core offers scientific consultation from project conception and execution to preparation of manuscripts and grant applications. Primary Core services are: 1) liquid chromatographic/mass spectrometry (LC/MS); 2) untargeted/targeted proteomics, including label-free quantitative proteomics as well as stable isotope labeling with isobaric tandem mass tags or stable isotope labeling of amino acids in culture; 3) identification and quantification of post- translational modifications; 4) de novo peptide/protein sequence analysis; 5) peptide sequence validation under GMP conditions (the Core is FDA-registered); 6) lipidomics and metabolomics; 7) biomarker discovery from clinical samples; 8) assay development and quantification of small molecules, peptides, drugs, and validation of potential biomarkers; 9) tissue biomarker profiling by MALDI-MS; and 10) tissue imaging mass spectrometry. The MMSBD is well equipped with cutting-edge major instrumentation including an Orbitrap Fusion Tribrid mass spectrometer (Thermo); a 6490 Triple Quadrupole mass spectrometer (Agilent); several LC Q-TOF mass spectrometers (Waters and Agilent), and two MALDI-MS instruments. A second high-end Orbitrap mass spectrometer (a Fusion Lumos; Thermo) is being purchased to meet increased demands for LC/MS instrument time. Data analyses are performed on Core-maintained workstations and multi-node computer clusters that operate both commercial and open source software. Software is constantly updated and MS and metadata are automatically backed up and stored on several redundant storage units located on and off the main campus. The core is co-directed by Drs. Markus Kalkum and Robert Hickey, who are both faculty within Beckman Research Institute. Key decisions affecting the Core are reviewed by an Advisory Committee, composed of CC members who use the Core?s services. Since the last competitive renewal, the MMSBD contributed to 26 publications by CC members and served 73 investigators, 52 of whom were CC members representing all five Programs. Of the 52 CC members, 45 (87%) had peer-reviewed funding. Accordingly, the MMSBD provides accessible, cost-effective, and high-quality multi-omics mass spectrometry and biomarker discovery services to support the research of the City of Hope Comprehensive Cancer Center.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beckman Research Institute/City of Hope
United States
Zip Code
Querfeld, Christiane; Leung, Samantha; Myskowski, Patricia L et al. (2018) Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunol Res 6:900-909
Liu, Xuxiang; Cao, Minghui; Palomares, Melanie et al. (2018) Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res 20:127
Das, Sadhan; Reddy, Marpadga A; Senapati, Parijat et al. (2018) Diabetes Mellitus-Induced Long Noncoding RNA Dnm3os Regulates Macrophage Functions and Inflammation via Nuclear Mechanisms. Arterioscler Thromb Vasc Biol 38:1806-1820
Al Malki, Monzr M; Nathwani, Nitya; Yang, Dongyun et al. (2018) Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1828-1835
Chiuppesi, Flavia; Nguyen, Jenny; Park, Soojin et al. (2018) Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice. J Virol 92:
Petrossian, Karineh; Kanaya, Noriko; Lo, Chiao et al. (2018) ER?-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer. Oncotarget 9:27736-27751
Ambaye, Nigus; Chen, Chih-Hong; Khanna, Swati et al. (2018) Streptonigrin Inhibits SENP1 and Reduces the Protein Level of Hypoxia-Inducible Factor 1? (HIF1?) in Cells. Biochemistry 57:1807-1813
Bosworth, Alysia; Goodman, Elizabeth L; Wu, Eric et al. (2018) The Minneapolis-Manchester Quality of Life Instrument: reliability and validity of the Adult Form in cancer survivors. Qual Life Res 27:321-332
Vu, Binh Thanh; Shahin, Sophia Allaf; Croissant, Jonas et al. (2018) Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Sci Rep 8:8524
Yan, Wei; Wu, Xiwei; Zhou, Weiying et al. (2018) Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol 20:597-609

Showing the most recent 10 out of 1396 publications